A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma

被引：0
|
作者：
Lee, C-H. [1 ]
Makker, V. [1 ]
Rasco, D. [2 ]
Taylor, M. [3 ]
Dutcus, C. [4 ]
Shumaker, R. [4 ]
Schmidt, E. V. [5 ]
Stepan, D. [4 ]
Li, D. [4 ]
Motzer, R. J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[2] START, Med Oncol, San Antonio, TX USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[4] Eisai Inc, Woodcliff Lake, NJ USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
847O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
    Choueiri, T. K.
    Plimack, E. R.
    Gupta, S.
    Cho, D.
    Hutson, T. E.
    Puzanov, I.
    George, S.
    Olencki, T.
    Vaishampayan, U.
    Chakrabarti, D.
    Pithavala, Y. K.
    Williams, J. A.
    Rosbrook, B.
    Tarazi, J. C.
    Atkins, M. B.
    [J]. BJU INTERNATIONAL, 2014, 114 : 4 - 5
  • [32] Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population
    Fujiwara, Ryo
    Yuasa, Takeshi
    Kobayashi, Kenichi
    Yoshida, Tetsuya
    Kageyama, Susumu
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 461 - 469
  • [33] A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
    Makker, Vicky
    Rasco, Drew W.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Li, Di
    Schmidt, Emmett V.
    Shumaker, Robert Charles
    Taylor, Matthew H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report
    Villatore, Andrea
    Bosi, Carlo
    Pomaranzi, Chiara
    Cigliola, Antonio
    Tateo, Valentina
    Mercinelli, Chiara
    Vignale, Davide
    Rizzo, Stefania
    Necchi, Andrea
    Peretto, Giovanni
    [J]. CARDIOVASCULAR TOXICOLOGY, 2024, 24 (11) : 1168 - 1173
  • [35] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [36] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Gruenwald, V.
    Powles, T.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C.
    Motzer, R.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Winquist, E.
    Goh, J. C.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Burgents, J. E.
    Perini, R.
    He, C.
    Okpara, C. E.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ONKOUROLOGIYA, 2024, 20 (01): : 24 - 35
  • [37] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
    Lee, C-H.
    Adachi, Y.
    Ikezawa, H.
    Li, S. D.
    Funahashi, Y.
    Minoshima, Y.
    Kubiak, P.
    Perini, R.
    Ren, M.
    Smith, A. D.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S564 - S565
  • [38] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [39] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [40] Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
    Pal, Sumanta K.
    Puente, Javier
    Heng, Daniel Y. C.
    Glen, Hilary
    Koralewski, Piotr
    Stroyakovskiy, Daniil
    Alekseev, Boris
    Parnis, Francis
    Castellano, Daniel
    Ciuleanu, Tudor
    Lee, Jae Lyun
    Sunela, Kaisa
    O'Hara, Karen
    Binder, Terri A.
    Peng, Lixian
    Smith, Alan D.
    Rha, Sun Young
    [J]. EUROPEAN UROLOGY, 2022, 82 (03) : 283 - 292
12345